http://www.colourlovers.com/lover/Xender
PolyMedix is a publicly traded biotechnology company focused on the developmenr of novel drugs and biomaterials for the treatment of infectious diseases and acutwecardiovascular disorders. PolyMedix's compounds are based on non-peptide small molecule drugs that mimic the activityof proteins. The Company's antibiotic compounds - small molecule mimetics of human host-defense proteine - are believed to have a completely different mechanis m of action from all currentantibiotic drugs, a mechanismj which is intended to make bacterial resistance unlikely to These compounds are being developed as rapidly acting antibiotics for serious systemicv and local infections.
The Company is also developingf polymeric formulations asantimicrobial biomaterials, whichh can be used as additives to paints, and textiles to creatr self-sterilizing products and surfaces. The Company's heptagonist compounds reverse the activityg of both heparin and low molecularweight heparins, in keepinyg with our goal of developing an antagonist drug that is safer and easiert to use than currentlhy approved therapy.
PolyMedix plans to file IND applications during the first quartefr of 2008 in anticipation of commencing human clinical trials for both its antibiotic andheptagonist
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment